In fact, while BRCA1 and BRCA2 mutation status are positive predictors of PARP1 inhibitor response due to synthetic lethality in the setting of other tumor types, this is not a requirement and other gene signatures can serve as predictors of therapeutic response where the use of single molecular markers prove to be insufficient (44). Here, PARP1 is linked to neoplasm.